aap Implantate AG: Management Board refines 2026 forecast and provides first outlook for 2027 – Ambition 2030: Revenue of at least EUR 21 million with an EBITDA margin of 17.5% to 22.5%

aap Implantate AG

/ Key word(s): Forecast

aap Implantate AG: Management Board refines 2026 forecast and provides first outlook for 2027 – Ambition 2030: Revenue of at least EUR 21 million with an EBITDA margin of 17.5% to 22.5%

11.11.2026 / 08:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


aap Implantate AG: Management Board refines 2026 forecast and provides first outlook for 2027 – Ambition 2030: Revenue of at least EUR 21 million with an EBITDA margin of 17.5% to 22.5%

  • 2026 Forecast Clarified: Revenue of EUR 12.0 million to EUR 13.0 million, EBITDA of EUR -0.5 million to EUR +0.5 million
  • These figures are based on the approved business plans and the published nine-month results: Q3 2026 revenue of EUR 3.3 million (+2%), EBITDA after nine months above the IFRS break-even point
  • Outlook for 2027: Revenue of at least EUR 14 million, EBITDA ranging from EUR 0.0 million to EUR 2.0 million
  • 2030 Ambition: Revenue of at least EUR 21 million and an EBITDA margin of 17.5% to 22.5% at steady state
  • Growth drivers: sales expansion, expanded product portfolio, and more efficient manufacturing in Berlin
  • Updated investor presentation now available at www.aap.de

Berlin, November 11, 2026 – The Management Board of aap Implantate AG (“aap,” ISIN: DE000A3H2101), a manufacturer of “Made in Germany” trauma implants, has clarified its forecast for fiscal year 2026 following the approval of the business plans and based on business performance in the first nine months, and has presented, for the first time, a quantified outlook for fiscal year 2027 as well as a medium-term ambition through 2030. In doing so, the Management Board is establishing a solid foundation for investors and providing a clear and verifiable outlook for the coming years.

2026 Forecast: Ranges Narrowed Following Approval of Business Plans

As previously reported, aap generated revenue of EUR 3.3 million in the third quarter of 2026, up 2% from the same quarter a year earlier. After nine months, consolidated revenue totaled EUR 9.35 million (9M/2025: EUR 9.48 million). EBITDA under IFRS was above the break-even point in the first nine months.

With the approval of the business plans, management now has the necessary visibility to refine the forecast for the current fiscal year and lay a solid foundation for 2027. For 2026, revenue is now expected to range from EUR 12.0 million to EUR 13.0 million (previously: EUR 11.5 million to EUR 14.5 million) and EBITDA from EUR -0.5 million to EUR +0.5 million (previously: EUR -1.0 million to EUR +1.5 million). The midpoint of the new revenue range, at EUR 12.5 million, corresponds to the previous year’s revenue. The new EBITDA range falls within the middle of the previous forecast range. The Management Board thus confirms the expectation expressed in the Corporate News release of November 2, 2026, of positive EBITDA in the middle of the forecast range.

Rubino Di Girolamo, Chief Executive Officer (CEO) of aap Implantate AG, explains:

“We have restructured aap in recent years, completed the MDR transformation, and established the structures for growth. The foundation has been laid. The new Management Board team led by Cornelius Fink, and Nicole Kassel will consistently continue this development. The targets presented today provide a clear and binding framework for this.”

Outlook for 2027: Revenue of at least EUR 14 million – three growth drivers with high visibility

For fiscal year 2027, the Management Board expects revenue of at least EUR 14 million and EBITDA of between EUR 0.0 million and EUR 2.0 million. Based on the midpoint of the 2026 forecast, this corresponds to revenue growth of approximately 12%. With this, aap further specifies the previously communicated goal of average double-digit revenue growth starting in 2027.

The planned growth is based on three drivers that have already been initiated:

Existing customers – approx. EUR 0.7 million: Additional revenue from new product launches with existing customers.

International – approximately EUR 1.0 million: Additional sales staff as well as market entry or expansion in ten additional countries.

aap Implants Inc. (US) – approximately EUR 1.0 million: Expansion of the US sales team, revenue from new products, and improved utilization of implant sets already on the market.

About three-quarters of the planned growth is thus expected to come from international business and the US subsidiary – the areas that have already shown the most dynamic growth in the first nine months of 2026.

Ambition 2030: Revenue of at least EUR 21 million and an EBITDA margin of 17.5% to 22.5%

To provide investors with a clear medium-term outlook, the Management Board has set an ambition for 2030: revenue of at least EUR 21 million and an EBITDA margin of 17.5% to 22.5% in a steady-state scenario – that is, after the launch of new products and assuming a stable market environment. Based on 2025 revenue of EUR 12.5 million, this corresponds to an average annual growth rate of approximately 11%. Compared to the previously cited revenue figure of approximately EUR 20 million for 2030, the Management Board is thus setting a clear lower limit and, for the first time, quantifying the targeted profitability. The 2030 ambition applies exclusively to the trauma business. Potential revenue from antibacterial silver technology – for which initial approval is expected no earlier than 2030 – is not included in this figure. However, it represents another potential growth driver.

Three value drivers are intended to support this path: investments in production capacity and technology at the Berlin site – including new lathes and milling machines as well as robotics and automation – the further expansion of sales capacity in Europe, the US, and new markets, and an expanded product portfolio with eleven development projects through 2031. Once the planned portfolio expansion is complete, the product range is expected to cover approximately 90% of the human body – all regions except the spine and skull. In terms of margins, aap benefits from a gross margin of approximately 90%, economies of scale, and increasingly automated manufacturing.

Cornelius Fink, Member of the Management Board (COO) of aap Implantate AG, explains:

“New manufacturing facilities and more efficient production processes have been implemented. This allows us to manufacture more productively in Berlin and create the capacity needed for our planned growth. At the same time, efficient production is the key driver for achieving the margin we have set as our goal for 2030.”

Nicole Kassel, Member of the Management Board (CFO) of aap Implantate AG, adds:

“The proceeds from the capital increase are financing the implementation of our plans – from expanding sales and developing new products to further automating production. Our goals for 2027 are built on a solid foundation, and we look forward to our 2030 target with full confidence.”

Investor Presentation and Munich Capital Markets Conference

A short video and the updated 2026 investor presentation, featuring forecasts, an outlook, and our 2030 ambition, are now available in the Investor Relations section at www.aap.de. aap will present the materials on November 11, 2026, at the Munich Capital Markets Conference (MKK) as well as in one-on-one meetings with investors. The subscription period for the current capital increase ends on November 20, 2026.

About aap Implantate AG

Headquartered in Berlin, aap Implantate AG develops, manufactures, and distributes implants for trauma surgery. At the core of its portfolio is the patented LOQTEQ® plate system, which combines fracture compression and angle-stable fixation in a single surgical step. All existing products are MDR-certified and are 100% manufactured in Berlin. In Germany, aap sells directly to hospitals and purchasing groups; internationally, it sells through distributors; and in the US, through its subsidiary aap Implants Inc. Product registrations are in place in 46 countries. In addition, aap has a patented antibacterial silver-coating technology that has already passed clinical trials and is seeking approval. The stock is listed on the regulated market of the Frankfurt Stock Exchange (General Standard) (ISIN: DE000A3H2101, WKN: A3H210).

www.aap.de

Investor Relations Contact:

CROSS ALLIANCE communication GmbH
Susan Hoffmeister
Phone: +49 89 125 09 0333
Email: sh@crossalliance.de
www.crossalliance.de

 

Important Notice

This announcement is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for securities of aap Implantate AG. The offering is governed exclusively by the subscription offer published in the Federal Gazette. This announcement is not intended for publication or distribution in or within the United States of America, Canada, Australia, or Japan. It may contain forward-looking statements based on the current expectations of the Executive Board and subject to risks and uncertainties; actual results may differ materially.

Contact:
If you have any questions, please contact:
aap Implantate AG; R. Di Girolamo; Chairman of the Executive Board / CEO; Lorenzweg 5; D-12099 Berlin
Phone: +49/30/750 19 – 170; Fax: +49/30/750 19 – 290; r.digirolamo@aap.de


11.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Germany
Phone: +49 (0) 30 75 019-0
Fax: +49 (0) 30 75 019-111
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE000A3H2101
WKN: A3H210
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX
LEI Code: 39120001TRQTQ01LPP57
EQS News ID: 2431806

 
End of News EQS News Service

2431806  11.11.2026 CET/CEST

BioVersys and partners to present AlpE data at The Union World Conference on Lung Health

Basel, Switzerland. November 11, 2026, 7.00am CEST

 

BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today that it will present new data on alpibectir together with its development partner GSK. The Union World Conference on Lung Health is taking place from 17 to 20 November 2026 in Rio de Janeiro, Brazil.

Presentations will include the latest Phase 2 data on alpibectir in combination with ethionamide (AlpE), in patients with newly diagnosed drug-sensitive pulmonary tuberculosis.

The Union World Conference on Lung Health brings together researchers, practitioners, advocates, policymakers and communities from around the world to share knowledge, exchange ideas and accelerate progress in lung health.

 

Alpibectir data presentation schedule at the Union Conference

Date and time (BRT)

Presenter

Presentation

Session

Wednesday, 18 November
12:15–12:20

Dr. Simphiwe RN Simelane

E-poster: “Early bactericidal activity, safety, and pharmacokinetics of alpibectir–ethionamide in pulmonary tuberculosis”

EP16
Emerging therapeutics in TB safety, efficacy and early activity

Thursday, 19 November
09:58–10:06

Dr. Michel Pieren, BioVersys

“Alpibectir potentiates ethionamide and ethionamide-sulfoxide activity in M. tuberculosis clinical isolates from a Phase 2a study”

OA24
Alchemy: Dose determination, safety and adverse effects in preclinical and clinical TB trials

Thursday, 19 November
10:16–10:30

Dr. Simphiwe RN Simelane

“Early bactericidal activity, safety and PK of alpibectir-ethionamide in pulmonary tuberculosis: Results from the ENABLE trial”

SY08
Reimagining TB drug development: Phase 2 results from the UNITE4TB platform

Friday, 20 November
13:11–13:28

Dr. Simon Tiberi

“Early bactericidal activity, safety and PK of alpibectir-ethionamide and updates on further development of alpibectir-containing TB regimens”

SS12
Tackling tuberculosis today and for the future: From pipeline innovation to global collaboration

Satellite session: 12:15–13:45; chaired by David Barros-Aguirre

 

FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor

FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor




FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor

  • PIMJETMI is a new once-daily oral systemic treatment option for certain U.S. patients with symptomatic tenosynovial giant cell tumor (TGCT)
  • In the Phase 3 MANEUVER trial, PIMJETMI demonstrated early1 and durable2 tumor response with clinically meaningful improvements in all clinical outcome assessments, including physical function and pain
  • PIMJETMI has shown high objective response rate (ORR) with a manageable safety profile

Not intended for Canada-, UK- or US-based media


DARMSTADT, Germany–(BUSINESS WIRE)–Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has approved PIMJETMI® (pimicotinib), a once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor, as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity.

“People living with TGCT have long faced difficult treatment decisions as they navigate a disease that can significantly affect their daily lives including their mobility,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board for the Healthcare business of Merck. “Translating scientific innovation into clinically meaningful advances for people living with rare tumors is a strategic imperative for our company, as we continue our commitment to addressing significant unmet needs. With the approval of PIMJETMI in the U.S., we strengthen our leadership position and growing portfolio in rare tumors and bring real hope to patients and their families.”

TGCT is a rare, locally aggressive tumor occurring in or around the joints leading to progressive worsening of symptoms including pain and reduced mobility of the affected joint, significantly impacting physical function in what is typically an otherwise healthy and young population. It has been reported that up to half of people with TGCT can be initially misdiagnosed, resulting in delays in the appropriate disease management.3 If left untreated or in recurrent cases, TGCT may result in cumulative morbidity and irreversible damage to the bone, joint and surrounding tissues.

“The results of the Phase 3 MANEUVER trial demonstrate that PIMJETMI elicits durable2 tumor response with a manageable tolerability profile,” said Vinod Ravi, MD, MS, MBA, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, UT MD Anderson, an investigator on the MANEUVER trial. “This combination of efficacy and safety data will potentially address the needs of people living with TGCT in a once-daily treatment option.”

FDA approval is based on primary and longer-term results from the global Phase 3 MANEUVER study. PIMJETMI demonstrated a statistically significant improvement in objective response rate (ORR) at week 25 as assessed by blinded independent review committee (BIRC) based on RECIST v1.1 compared with placebo (56% vs. 3% for placebo; p<0.0001). PIMJETMI also demonstrated clinically meaningful and statistically significant improvements as compared to placebo across secondary endpoints relevant to patients’ daily lives, improving relative range of motion (p=0.0003), physical functioning (p=0.0074), and pain (p<0.0001). The MANEUVER study was presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. In the longer-term follow up (median 14.3 months for patients initially randomized to pimicotinib) presented at the European Society for Medical Oncology (ESMO) Congress in 2025, the median duration of response was not reached. The majority (77%) of patients with response at 25 weeks maintained clinical benefit after an additional 12 months of follow up, demonstrating the durability2 of response with PIMJETMI.

In MANEUVER, pimicotinib was well-tolerated, with no evidence of cholestatic hepatotoxicity or hair/skin hypopigmentation. During the randomized, double-blind treatment phase of the trial, treatment-emergent adverse events (TEAEs) leading to treatment discontinuation occurred in one patient (1.6%) treated with pimicotinib; TEAEs leading to dose reduction occurred in 7.9% (n=5) of pimicotinib-treated patients.

“TGCT can profoundly affect patients’ daily lives through persistent pain, swelling, and loss of joint function,” said Sydney Stern, PhD, MS, TGCT Support, a Program of the Life Raft Group. “For symptomatic patients who are not likely to benefit from surgery alone, there remains need for treatment options which are tolerable and effectively address the burden of disease, shrink their TGCT, and improve pain and function.”

The FDA approval of PIMJETMI builds on growing momentum for the Merck rare tumors portfolio that included two other drug approvals in the past three years including OGSIVEO®, the first FDA-approved treatment for adults with progressing desmoid tumors who require systemic therapy. The PIMJETMI approval follows its approval in China by the National Medical Products Administration (NMPA) in December 2025, in Canada by Health Canada in June 2026 for the treatment of adult patients with symptomatic TGCT, as well as in Switzerland by its own independent national regulatory authority, the Swissmedic in October 2026.

The application for PIMJETMI was reviewed under Project Orbis, an international initiative of the FDA Oncology Center of Excellence. Application reviews are ongoing for partners of Project Orbis, an international framework for collaboration.

1 In the global Phase 3 MANEUVER clinical trial, the effect of pimicotinib had an early onset, with 41.3% (26 of 63) of patients experiencing objective response to therapy after 13 weeks.
2 The majority (77%) of patients with response at 25 weeks maintained this clinical benefit after an additional 12 months of treatment.

3 Stern S, et al. Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry. Future Oncol. 2025;21(12):1501-1510.

About MANEUVER

The pivotal, global, Phase 3 MANEUVER study is a three-part, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of PIMJETMI in patients with TGCT who were eligible for systemic therapy and have not received prior anti-CSF-1/CSF-1R therapy.

The ongoing study is being conducted by Abbisko Therapeutics and enrolled patients globally in USA, Canada and Europe (n=49) and China (n=45).

In the double-blind Part 1, 94 patients were randomized 2:1 to receive either 50 mg QD of PIMJETMI (n=63) or placebo (n=31) for 24 weeks. In addition to the primary endpoint of ORR at week 25, as measured by RECIST v1.1 by BICR, secondary endpoints include tumor volume score (TVS), relative range of motion, pain by Brief Pain Inventory (BPI), and physical function measured by Patient-Reported Outcomes Measurement Information System (PROMIS-PF).

After the double-blind Part 1, all eligible patients from either arm could continue to the open-label Part 2 and receive up to 24 weeks of pimicotinib treatment. Patients who completed Part 2 could then enter the open-label extension phase (Part 3) for extended treatment and safety follow-up.

About PIMJETMI® (pimicotinib)

PIMJETMI, developed by Abbisko Therapeutics, is a novel, orally administered, highly selective and potent small-molecule inhibitor of CSF-1R. PIMJETMI has been approved for the treatment of adult patients with symptomatic TGCT for which surgical resection will potentially cause functional limitation or relatively severe morbidity by China National Medical Products Administration (NMPA) and Health Canada. PIMJETMI has received priority medicine (PRIME) designation from the European Medicines Agency (EMA). Merck holds worldwide commercialization rights for PIMJETMI.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2025, Merck generated sales of € 21.1 billion in 65 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Contacts

Gangolf Schrimpf
gangolf.schrimpf@merckgroup.com
Phone: +49 151 1454-9591

Investor Relations

investor.relations@merckgroup.com
Phone: +49 6151 72-3321

aap increases revenue by 2% in the third quarter of 2026 – on top of the already high prior-year level

aap Implantate AG

/ Key word(s): Quarter Results/9 Month figures

aap increases revenue by 2% in the third quarter of 2026 – on top of the already high prior-year level

10.11.2026 / 11:04 CET/CEST

The issuer is solely responsible for the content of this announcement.


aap increases revenue by 2% in the third quarter of 2026 – on top of the already high prior-year level

  • Q3 revenue rises 2% to EUR 3.3 million – strong prior-year quarter surpassed once again; revenue performance improves year-to-date
  • U.S. business grows by 2% in local currency in Q3 on a high prior-year basis; highest monthly order intake of the year at the start of Q4
  • EBITDA continued to improve in the first nine months of 2026 and remained above the break-even point under both and IFRS

Berlin, November 10, 2026

aap Implantate AG (“aap”) continued its operational recovery in the third quarter of 2026. Compared to the previous quarter, revenue rose from EUR 2.8 million to EUR 3.3 million, slightly exceeding the level of the same quarter last year. For the first nine months of 2026, this results in a revenue decline of only 1.4% compared to the same period last year. This reflects a gradual improvement in revenue performance over the course of the year.

Q3/2026 – Revenue Figures

Region / Revenue in kEUR Q3/2026 Q3/2025 Change
EMEA (= Europe, Middle East, Africa)
North America
LATAM (= Latin America)
APAC (= Asia-Pacific)
1,521
797
832
184
1,481
732
828
214
3%
9%
0%
-14%
Revenue 3,334 3,255 2%

 

Region / Revenue in kUSD Q3/2026 Q3/2025 Change
North America 875 855 2%

9M/2026 – Revenue Figures

Revenue in kEUR 9M/2026 9M/2025 Change
EMEA (= Europe, Middle East, Africa)
North America
LATAM (= Latin America)
APAC (= Asia-Pacific)
4,546
2,280
1,929
597
4,753
2,022
2,047
663
-4%
13%
-6%
-10%
Revenue 9,352 9,484 -1%

 

Region / Revenue in kUSD 9M/2026 9M/2025 Change
North America 2,607 2,266 15%

 

Regional Revenue Trends

EMEA, the region with the highest revenue, posted revenue growth of 3% in the third quarter of 2026 compared with the same quarter of the previous year. In the Middle East, revenue recovered significantly, rising 22% compared with the same quarter of the previous year. However, revenue there remained 51% below the prior-year level for the first nine months. New products drove dynamic growth in Spain and Portugal and offset the decline in revenue in South Africa. Most other markets in the region saw slight increases or decreases in revenue in the third quarter.

The US business remained a key growth driver for the Group. As early as the third quarter of 2025, aap had already increased revenue by 18% compared with the same quarter of the previous year. Against this high comparative base, revenue grew by an additional 2% in local currency in the third quarter of 2026. The fourth quarter also began with the highest monthly order intake of the year.

In the LATAM region, revenue matched the level of the exceptionally strong prior-year quarter, in which 21% growth had been achieved. An expanded product portfolio and new markets offset the high one-time orders from the third quarter of 2025. This creates a solid foundation for the coming year. For the fourth quarter, aap is confident that it will further reduce the cumulative revenue shortfall compared to the prior year.

In the APAC region, revenue in the third quarter was 14% below the prior-year figure. The comparable quarter of 2025 had been exceptionally strong, with growth of over 200%. For the fourth quarter, aap is confident that it will make further progress and generate additional growth on the region’s continuously expanding foundation.

Revenue and Earnings Performance in the First Nine Months

The strong third quarter helped narrow the year-over-year revenue shortfall in the first nine months. Cumulative revenue reached EUR 9.3 million (9M/2025: EUR 9.5 million).

Earnings performance also remained positive: EBITDA improved again in the first nine months of 2026 and was above the break-even point under IFRS. This underscores the progress made in efficiency, cost control, and operational performance.

Outlook for the Fourth Quarter

aap is starting the fourth quarter on a solid footing. A corresponding outlook is included in the investor presentation, which on our website will be available starting November 11, 2026.

 

About aap Implantate AG

aap Implantate AG is a globally active medical technology company headquartered in Berlin, Germany. The company develops, manufactures, and markets products for traumatology. In addition to the innovative LOQTEQ® anatomical plate system, its IP-protected portfolio includes a wide range of cannulated screws. Furthermore, aap Implantate AG has an innovation pipeline featuring promising development projects, such as antibacterial silver-coating technology and magnesium-based implants. These technologies address critical problems in traumatology that have not yet been adequately solved. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups, and hospital networks, while internationally it primarily relies on a broad network of distributors in approximately 25 countries. In the U.S., the company, through its subsidiary aap Implants Inc., employs a sales strategy based on distribution agents. The shares of aap Implantate AG are listed on the General Standard segment of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further information, please visit our website at www.aap.de.

The figures presented in this release may contain technical rounding differences that do not affect the overall message.

Contact Investor Relations:

CROSS ALLIANCE communication GmbH
Susan Hoffmeister
Phone: +49 89 125 09 0333
Email: sh@crossalliance.de
www.crossalliance.de

Important notice

This announcement is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for securities of aap Implantate AG. The offering is governed exclusively by the subscription offer published in the Federal Gazette. This announcement is not intended for publication or distribution in or within the United States of America, Canada, Australia, or Japan. It may contain forward-looking statements based on the current expectations of the Management Board and subject to risks and uncertainties; actual results may differ materially.

 

Forward-Looking Statements

This press release may contain forward-looking statements based on the current expectations, assumptions, and forecasts of the Executive Board, as well as on information currently available to it. The forward-looking statements are not to be construed as guarantees of the future developments and results mentioned therein. Various known and unknown risks, uncertainties, and other factors may cause the company’s actual results, financial position, development, or performance to differ materially from the estimates provided herein. These factors also include those described by aap in published reports. Forward-looking statements are therefore valid only as of the date they are made. We assume no obligation to update the forward-looking statements made in this press release or to adapt them to future events or developments.

 

Contact:
If you have any questions, please contact:
aap Implantate AG; R. Di Girolamo; Chairman of the Executive Board / CEO; Lorenzweg 5; D-12099 Berlin
Phone: +49/30/750 19 – 170; Fax: +49/30/750 19 – 290; r.digirolamo@aap.de


10.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Germany
Phone: +49 (0) 30 75 019-0
Fax: +49 (0) 30 75 019-111
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE000A3H2101
WKN: A3H210
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX
LEI Code: 39120001TRQTQ01LPP57
EQS News ID: 2431698

 
End of News EQS News Service

2431698  10.11.2026 CET/CEST

China Explores a New Pathway for Medical AI: Bridging R&D Innovation and Clinical Adoption

EQS Newswire / 10/11/2026 / 17:40 UTC+8

DIAGENS (HKEX: 02526.HK) advances an innovative model to lower barriers for specialised medical imaging AI development and real-world clinical implementation.

HANGZHOU, Nov. 10, 2026 —For enterprises advancing medical AI commercialisation, hospitals are the ultimate testing ground for real-world validation. Algorithms must target specific clinical pain points, adapt to local imaging datasets, and integrate seamlessly with frontline operational workflows. However, replicating customised development and adaptation work across individual healthcare institutions hinders scalable expansion and drives up costs.

Now, a newly launched partnership in southern China presents a model for restructuring medical AI application workflows. On 6 November, Hangzhou Diagens Biotechnology Co., Ltd. (DIAGENS, HKEX: 02526.HK), a Hong Kong-listed medical imaging AI player, entered into a three-year strategic cooperation agreement with Yongjiang Laboratory in Guangxi. The cooperation covers model training, multi-centre clinical validation and the implementation of demonstration projects, with cross-border cooperation in Southeast Asia as a long-term objective.

This partnership aligns with China’s broader strategy of integrating AI innovation with clinical practice. Public healthcare institutions, clinical teams and technology enterprises are jointly building a process to accelerate the integration of specialty AI models into mainstream healthcare workflows.

 

Translating Clinical Requirements into AI-enabled Solutions

Diagens anchors its technological system on iMedImage®, its reusable foundational medical imaging model. Its proprietary iMedLoop™ medical imaging AI R&D and production acceleration platform integrates key stages including data processing, intelligent annotation, quality control, model training, unified evaluation, release, deployment and application feedback. Clinical teams define clinical requirements and task specifications based on their professional expertise, while Diagens offers a technical foundation and tailored tools to develop task-specific AI models.

This paradigm delivers distinct advantages. Teams developing CT diagnostic models for renal diseases and X-ray models for breast conditions operate in different scenarios, yet they can share underlying R&D infrastructure. The reuse of foundational capabilities optimises cost allocation across multiple scenarios and enables hospitals to launch projects without assembling large technical teams.

Guangxi has already witnessed practical achievements. Leveraging the core technologies of Diagens, local hospital teams have developed CT diagnostic models for renal cancers and X-ray diagnostic models for breast cancers, securing awards in a national medical imaging AI competition held by China’s National Healthcare Security Administration. These successful cases demonstrate how clinicians participate in scenario-oriented AI model development. The new laboratory cooperation in Guangxi aims to scale up such collaborative models.

The business model can scale along two dimensions. Individual healthcare institutions can develop multiple AI-enabled diagnostic tools, while mature solutions can be iterated and adapted for deployment across diverse healthcare facilities. The competitive advantage derives from the transfer of technical experience and clinical insights across projects.

 

Transformative Impacts of Industry Policy Support

China’s policies have paved a clear pathway for the clinical implementation of this collaborative model. A national healthcare plan released in November 2025 sets clear development targets: specialty models and AI agents are to be fully established by 2027, and AI-assisted medical imaging tools shall achieve universal adoption in secondary-level and higher hospitals nationwide by 2030.

These targets deliver tangible value by integrating all essential resources, including participating hospitals, clinical specialists, professional evaluation systems and technical capabilities. The systematic coordination of these core elements constitutes a critical step in accelerating the implementation of medical AI technologies.

Diagens’ cooperation framework agreement with Zhejiang Anzhen’er Medical Artificial Intelligence Technology Co., Ltd. (“Anzhen’er”), signed in September 2026, serves as a typical case. As the operating entity of the National Artificial Intelligence Application Pilot Base (Medical) in Zhejiang, Anzhen’er plans to explore an integrated service model with Diagens, combining on-site medical examinations, cloud-based AI analysis and specialist manual review. This framework standardises the role of AI technologies in clinical workflows and enables grassroots healthcare institutions to access high-quality shared resources.

Guangxi presents a different healthcare ecosystem. By the end of 2025, this province hosted 940 hospitals and 1,258 township healthcare centres. Clearly, cross-institutional collaboration requires adaptive optimisation for differentiated equipment configurations, staffing structures and computing resources. Successful implementation in Guangxi will generate replicable experience for other regions grappling with similar resource gaps between large hospitals and grassroots healthcare facilities.

Policy incentives run parallel to rigorous product supervision. In May 2026, Diagens obtained Class III medical device registration for its AI AutoVision™ chromosome analysis system in China. This milestone validates Diagens’ capability to translate imaging AI technologies into fully compliant, commercially available clinical products via regulatory approval pathways.

 

Technical Capabilities Underpinning Clinical Deployment

As disclosed in Diagens’ 2025 annual report, its iMedImage® foundational model features 104 billion parameters, covering 19 imaging modalities and 26 clinical specialties. The extensive coverage aligns with the strategic goal of supporting diversified specialty-specific scenarios based on a unified foundational model. The model enables multi-level image analysis tasks, including classification, detection and segmentation.

Relevant technical reports demonstrate robust model performance. It achieves a chromosome classification accuracy rate of 99.96% based on 45,328 images. In end-to-end chromosomal abnormality analysis tasks leveraging data from 12 healthcare institutions, it delivers a sensitivity of 92.75% and a specificity of 91.50%. These task-specific results provide solid evidence for Diagens’ technical strengths, as its registered products mark substantial progress in clinical commercialisation.

Medical imaging represents a core frontier for the global development of foundational AI models. Google’s MedGemma 1.5 expands its capabilities to 3D CT, 3D MRI and whole-slide histopathology imaging scenarios, while Microsoft’s MedImageParse and MedImageParse3D enable segmentation, detection and recognition for 3D medical image analysis. These technological advances collectively reflect a clear industry trend: reusable foundational models are becoming the core infrastructure for diversified imaging tasks and specialty-specific applications.

The breadth of imaging modality coverage serves as a key indicator of competitiveness. Google’s MedGemma 1.5 covers six major imaging categories, including chest X-ray, CT, MRI, dermatological imaging, fundus imaging and histopathology. Microsoft’s MedImageParse supports nine imaging modalities, whereas iMedImage® from Diagens covers 19 modalities. Compared with mainstream foundational models, iMedImage® boasts industry-leading coverage of medical imaging scenarios, laying a solid foundation for the development of specialty AI models for diverse clinical tasks.

By integrating its foundational imaging capabilities, hospital-led customised model development, registered clinical products and revenue-generating model services, Diagens has established a leading position in the commercialisation of medical AI. Its core competitiveness lies in the closed-loop R&D system it enables: clinical expertise drives the iteration of specialty AI models, which are integrated into clinical workflows after rigorous evaluation. This unique enabling role differentiates Diagens in the global drive for standardised, scalable development and deployment of medical AI technologies.

 

Reuse-centric Commercialisation Model

This paradigm is backed by robust commercial performance. In the first half of 2026, Diagens recorded RMB 94.5 million in Model-as-a-Service (MaaS) revenue, representing a year-on-year surge of 101.1%. The revenue stream covers technology licensing, cloud-based services and on-premises deployment. As of 30 June, Diagens had launched 158 customised model projects in collaboration with 99 partner hospitals, building a solid client and R&D foundation for sustained business expansion.

The business model’s profitability hinges on reuse and iterative optimisation. Each project accumulates actionable experience in data processing, task definition, model evaluation and clinical deployment, which streamlines the delivery of subsequent projects, enabling the platform to support more scenarios without repetitive foundational R&D investment. Authorised clinical data and practitioner feedback further drive continuous model iteration and technological development.

As a Chinese province bordering Vietnam and with links to Southeast Asia, Guangxi unlocks new cross-border cooperation potential for Diagens. The experience accumulated across China’s tiered healthcare system will serve as a valuable reference for regional market expansion in Southeast Asia, where local clinical partnerships and scenario adaptation remain critical.

As a real-world example of China’s medical AI strategy, Diagens is committed to translating its reusable foundational AI model into an expanding portfolio of clinically validated tools. Its core growth opportunity lies in building a standardised and repeatable system, which significantly lowers the barriers to medical AI R&D and large-scale clinical implementation.

 

Contact

DUAN YU

DIAGENS Public Relations

duanyu@diagens.com

10/11/2026 Dissemination of a Financial Press Release, transmitted by EQS News.
The issuer is solely responsible for the content of this announcement.

Media archive at www.todayir.com

Cantourage Group SE Strengthens Profitability and European Market Position Despite Increasing Pricing Pressure

Cantourage Group SE

/ Key word(s): 9 Month figures/Quarter Results

Cantourage Group SE Strengthens Profitability and European Market Position Despite Increasing Pricing Pressure

10.11.2026 / 07:23 CET/CEST

The issuer is solely responsible for the content of this announcement.


– Q3 revenue: EUR 19.9 million (Q3 2025: EUR 20.3 million); gross margin: 35.3% (prior year: 18.1%)

– Q3 EBITDA: EUR 1.9 million (Q3 2025: EUR –2.2 million); EBITDA margin: 9.5%
– International business accounts for more than half of Group revenue; pricing pressure intensifies in Germany

Cantourage Group SE (“Cantourage”, ISIN: DE000A3DSV01) achieved a significantly positive operating result in the third quarter of 2026 despite increasing price competition in the German market. EBITDA improved from EUR –2.2 million in the prior-year quarter to EUR 1.9 million, while the EBITDA margin rose from –11.0% to 9.5%. With revenue of EUR 19.9 million (prior year: EUR 20.3 million), the gross margin increased from 18.1% to 35.3%. The consistent focus on higher-value, high-margin products and increasing diversification across several European markets are strengthening the resilience of the business model and contributing significantly to improved earnings quality.
In the first nine months of 2026, Cantourage generated revenue of EUR 62.3 million, EBITDA of EUR 6.8 million and an EBITDA margin of 10.9%. As of September 30, 2026, the equity ratio stood at 75.6%, while the net cash position amounted to EUR 10.8 million. This strong financial foundation provides Cantourage with the flexibility to further develop its product portfolio and expand its international presence.

Pricing Pressure in Germany – International Business Gains Importance
In Germany, Cantourage generated revenue of EUR 9.5 million in the third quarter (approximately 48% of Group revenue). According to the company, declining market prices for cannabis flowers and intensifying competition weighed on business performance. Cantourage is therefore deliberately focusing on differentiated premium product portfolios rather than pursuing additional volume at any cost.
The United Kingdom generated revenue of EUR 9.3 million (approximately 47%), while Poland contributed EUR 1.1 million (approximately 6%). Together, these two markets accounted for more than half of Group revenue, reducing the company’s dependence on the German market.
Monique Jaqqam, CFO of Cantourage Group SE, commented: “The significant year-on-year improvement in earnings demonstrates that our focus on high-margin products and our diversified presence across several European markets are delivering results. At the same time, we are systematically developing our finance organization. By establishing standardized processes and transitioning to IFRS, we are laying the foundation for greater transparency, reliability and international comparability.”

Three Key Drivers Strengthening the Competitive Position
With the successful completion of its third EU-GMP certification project involving All Nations, following Green Karat and LOT420, and the conclusion of five-year exclusive supply agreements, Cantourage is securing access to internationally sought-after premium cannabis products. These partnerships strengthen product differentiation and improve supply planning and predictability.
New active pharmaceutical ingredients based on distillates and extracts complement the existing cannabis flower portfolio and create opportunities for additional pharmaceutical applications.                                                                                            
Through the further development of Telecan, Cantourage is also expanding digital access to individually assessed, physician-led medical care. Medical decisions remain independent and under the responsibility of the treating physicians. For Cantourage, the strategic value lies in strengthening its presence within the healthcare ecosystem rather than enabling automated prescribing.

About Cantourage
Cantourage is a leading European company engaged in the production and distribution of medical cannabis preparations and pharmaceutical products. With its experienced management team and “Fast Track Access” platform, Cantourage enables producers from around the world to gain faster, easier and more cost-effective access to the growing European medical cannabis market. To this end, the company processes and distributes cannabis raw materials and extracts, consistently ensuring compliance with the highest European pharmaceutical quality standards. Cantourage offers pharmaceutical-grade products across all relevant market segments: dried cannabis flowers, extracts, dronabinol and cannabidiol. Cantourage has been listed on the Frankfurt Stock Exchange since 11 November 2022 (ISIN: DE000A3DSV01).

 


10.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Cantourage Group SE
Feurigstraße 54
10827 Berlin
Germany
E-mail: info@cantourage.com
Internet: https://www.cantourage.com/
ISIN: DE000A3DSV01
WKN: A3DSV0
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate BSX
LEI Code: 3912003NCTLO6YHA9V48
EQS News ID: 2431318

 
End of News EQS News Service

2431318  10.11.2026 CET/CEST

Medios Achieves Solid Revenue Growth in a Challenging Market Environment and Confirms Full-Year Forecast

Medios AG

/ Key word(s): Quarterly / Interim Statement/Quarter Results

Medios Achieves Solid Revenue Growth in a Challenging Market Environment and Confirms Full-Year Forecast

10.11.2026 / 07:05 CET/CEST

The issuer is solely responsible for the content of this announcement.


Press Release

Medios Achieves Solid Revenue Growth in a Challenging Market Environment and Confirms Full-Year Forecast

  • Consolidated revenue rises by 6.7% to €1,633.0 million in the first nine months of 2026; growth driven by all operating segments
  • EBITDA pre1 stands at €66.7 million (9M 2025: €70.4 million), with a margin of 4.1% (9M 2025: 4.6%)
  • Operating cash flow amounts to €26.2 million (9M 2025: €52.7 million)
  • Consistent implementation of the “Avanti Medios!” efficiency program is showing results
  • New “Medios Next Level” strategy presented at Capital Markets Day
  • Caelo acquisition completed; integration underway
  • Full-year forecast confirmed; EBITDA pre1 expected at the lower end of the range

Berlin, November 10, 2026 – The Medios Group (“Medios,” ISIN: DE000A1MMCC8), a European pharmaceutical services provider, increased its consolidated revenue by 6.7% to €1,633.0 million in the first nine months of 2026 (9M 2025: €1,530.0 million). All operating segments contributed to this growth.

EBITDA pre1 amounted to €66.7 million (9M 2025: €70.4 million); the EBITDA pre1 margin was 4.1% (9M 2025: 4.6%). Profitability was impacted by price declines for selected products in the Pharmaceutical Supply segment and temporarily higher material costs in the International Business.

Thomas Meier, CEO of Medios AG: “Despite a challenging market environment, we are growing in all operating segments. In Patient-Specific Therapies, we improved the EBITDA pre1 margin quarter-over-quarter for the third consecutive time. The consistent implementation of our efficiency program, Avanti Medios!, is contributing to this. Furthermore, with our new Medios Next Level strategy, we are streamlining our structure and placing a clear investment focus on expanding our compounding business.”

Segment Performance: Revenue Above Prior-Year Level
In the Pharmaceutical Supply segment, revenue rose by 6.8% to €1,323.5 million (9M 2025: €1,239.5 million). EBITDA pre1 declined by 9.1% to €35.3 million (9M 2025: €38.8 million). Price declines for selected products could not be fully offset by higher business volume. Additional earnings contributions from new business counteracted the price pressure, while personnel and other operating expenses increased at the same time. Since September, initial improvements in prices have become apparent.

The Patient-Specific Therapies segment increased its revenue by 8.4% to €180.0 million (9M 2025: €166.0 million). EBITDA pre1, at €17.7 million, was 2.3% below the prior-year level (9M 2025: €18.1 million), primarily due to drug price regulation. Higher sales volumes across all customer groups and the measures to improve operations helped offset this, but were unable to fully compensate for the decline.

In the International Business segment, external revenue grew by 4.1% to €129.3 million. EBITDA pre1 decreased by 7.7% to €20.3 million. In addition to temporarily higher material costs – particularly in connection with eye injections – increased personnel expenses weighed on the segment’s earnings. Furthermore, portfolio and divestment effects from the sale of non-core businesses in the prior year had positively impacted the previous year’s earnings by €2.6 million. Measures to improve profitability in the current financial year have been initiated.

Focus on Cash Flow
Operating cash flow for the first nine months of 2026 amounted to €26.2 million (9M 2025: €52.7 million). The 50.2% decline is primarily attributable to higher tax payments, lower earnings, cash proceeds from the sale of non-core businesses in the previous year and later payments to suppliers in the prior year. Working capital as of September 30, 2026, stood at €169.2 million (September 30, 2025: €136.8 million). To improve operating cash flow, Medios is focusing on optimizing capital tied up and cash conversion.

Capital expenditures (CapEx) totaled €10.3 million from January through September and were primarily attributable to the construction of a new building in Breda, the Netherlands. Free cash flow before acquisitions amounted to €15.9 million (9M 2025: €47.9 million). At the end of the reporting period, Medios had cash and cash equivalents of €92.2 million (9M 2025: €93.4 million). The net debt-to-EBITDA ratio stood at 1.2x, slightly below the prior-year level of 1.3x; the internal ceiling is 2.0x.

Stefan Bauerreis, CFO of Medios AG: “We are working intensively to ensure that our revenue growth is reflected more strongly in earnings and cash flow. That is why we are focusing on our operating cost base, capital tied up, and the swift implementation of the efficiency measures already initiated. At the same time, we continue to make targeted investments in the infrastructure we need for profitable growth.”

“Avanti Medios!” Is Having an Impact
As part of the “Avanti Medios!” efficiency program, Medios discontinued its activities in the Advanced Therapies business area and implemented restructuring measures at its Belgian subsidiary Magis Pharma in the third quarter. Prior to this, the closure of the Aschaffenburg site was completed. Total savings generated by the program amounted to €2.7 million as of September 30, 2026. Savings of €5 million are expected for the full year 2026. Beyond these individual measures, Medios is focusing on higher capacity utilization, efficient cost management, and the further optimization of its production network in Germany. The rollout of SAP S/4HANA is scheduled for January 1, 2027. It is intended to support process harmonization and thereby contribute to efficiency gains.

New “Medios Next Level” Strategy Unveiled
On September 29, 2026, Medios unveiled its new 2031 strategy, “Medios Next Level,” at its Capital Markets Day. It calls for a simplification of the Group’s structure and a clearly focused business model with two operating segments starting in 2027: Specialty Pharma Supply and Compounding. The focus is on profitable growth and targeted investments in the expansion of the European compounding business. Operational improvements, organic growth, and selective acquisitions are intended to strengthen profitability and cash generation. By 2031, Medios is targeting consolidated revenue of approximately €3.1 billion; at the same time, EBITDA adjusted2 is expected to double to around €170 million.

Caelo Strengthens the Compounding Business
Following the completion of the acquisition of a majority stake in Caesar & Loretz GmbH (Caelo), Medios has begun integrating the company. The initial consolidation took place on October 1, 2026; as a result, Caelo’s contribution is not yet included in the nine-month figures. Through this acquisition, Medios is expanding its Compounding Essentials business. Following a ramp-up phase, annual synergies of €3.4 million are expected from 2028/29 onwards.

Enhanced Financial Flexibility
All lending consortium banks have approved the increase and extension of Tranche B (RCF) under the existing term loan. The RCF (revolving credit facility) has thereby been increased to up to €125 million, with a further option to increase it to €150 million. The refinancing of the Caelo acquisition is thus already secured; at the same time, additional financial flexibility has been created under unchanged loan terms.

Full-Year Forecast Confirmed Despite “Hilfstaxe”
Medios confirms its forecast for the 2026 financial year, excluding M&A, with consolidated revenue between €2.10 and €2.16 billion and EBITDA pre1 between €88 and €92 million. The adjustment to the “Hilfstaxe” in Germany – the agreement between health insurance companies and pharmacists regarding the prices of preparations manufactured in pharmacies – is expected to place an additional burden of approximately €1.2 million on EBITDA pre1 in the Patient-Specific Therapies segment in the fourth quarter. The Executive Board therefore expects EBITDA pre1 to be at the lower end of the range.
 

Key figures (IFRS)                
in € million 9M 2026   9M 2025   ∆ in %
Consolidated revenue (extenal) 1,633.0   1,530.0   6.7
  Pharmaceutical Supply 1,323.5   1,239.5   6.8
  Patient-Specific Therapies 180.0   166.0   8.4
  International Business 129.3   124.2   4.1
  Services 0.4   0.4   6.2
EBITDA pre1 66.7   70.4   –5.2
  Pharmaceutical Supply 35.3   38.8   –9.1
  Patient-Specific Therapies 17.7   18.1   –2.3
  International Business 20.3   22.0   -7.7
  Services –6.6   –8.6   –22.7
Consolidated net income after income taxes 12.8   19.9   –35.9
Cash flow from operating activities 26.2   52.7   –50.2
Earnings per share (in €) 0.52   0.79   –34.0
Adjusted earnings per share (in €) 1.35   1.50   –10.0

¹ EBITDA is defined as consolidated earnings before interest, taxes, depreciation, and amortization. EBITDA pre is adjusted for extraordinary expenses related to stock options, expenses for M&A activities, expenses for the ERP system implementation, restructuring costs, and one-time expenses resulting from changes in the Executive Board.

2 For greater transparency in earnings, Medios will replace “EBITDA pre” with a newly defined “EBITDA adjusted” starting in the 2027 financial year. Going forward, adjustments will be limited to two clearly defined categories – M&A expenses and restructuring costs.

The Quarterly Statement as of September 30, 2026 is available on the Investor Relations website at investors.medios.group.

Important events for the Medios Group in the 2026 financial year

November 23-25, 2026 Equity Forum – Frankfurt, Germany
December 3, 2026 Berenberg European Conference, Fairmont Windsor Park, UK

—-

About Medios AG
Medios is a leading specialty pharmaceutical provider in Europe. With locations in Germany, the Netherlands, Belgium, and Spain, the company supports key partners in the supply chain with innovative solutions and smart services. Medios has focused on forward-looking personalized medicine to enable everyone to access the most innovative therapies in collaboration with pharmacies, specialist medical practices, and pharmaceutical companies.

Medios AG is Germany’s first publicly traded specialty pharmaceutical company. Medios AG shares (ISIN: DE000A1MMCC8) are traded on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) and are included in the SDAX index.

www.medios.group

Contact
Katrin Neuffer
Director of Investor Relations & Communications
Medios AG
Heidestraße 9 | 10557 Berlin
T +49 30 232 566 800
ir@medios.group
www.medios.group

Disclaimer
This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. Medios AG assumes no responsibility to update any forward-looking statements contained in this release.


10.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Medios AG
Heidestraße 9
10557 Berlin
Germany
Phone: +49 30 232 566 – 800
Fax: +49 30 232 566 – 801
E-mail: ir@medios.group
Internet: www.medios.group
ISIN: DE000A1MMCC8
WKN: A1MMCC
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
LEI Code: 391200Z7Z09IHDBT2L23
EQS News ID: 2431178

 
End of News EQS News Service

2431178  10.11.2026 CET/CEST

Qureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial

Qureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial




Qureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial

  • Qureight’s Fibr8 model to provide structural assessment as secondary endpoint in Contineum’s Phase 2 PROPEL-IPF clinical trial examining the safety and efficacy of PIPE-791 in idiopathic pulmonary fibrosis (IPF) patients
  • Announcement comes after a recent European Respiratory Journal viewpoint by Qureight CSO identifying fibrosis quantification as the key structural imaging biomarker needed for antifibrotic trials
  • PIPE-791 targets lysophosphatidic acid receptor 1 (LPAR1), a clinically validated target for IPF

CAMBRIDGE, England & SAN DIEGO–(BUSINESS WIRE)–Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum) (NASDAQ:CTNM), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight’s Fibr8™ quantitative imaging biomarker is being used as a secondary endpoint in Contineum’s PROPEL-IPF Phase 2 clinical trial examining the safety and efficacy of PIPE-791, Contineum’s lead drug candidate, in idiopathic pulmonary fibrosis (IPF) patients.


Forced Vital Capacity (FVC), the primary endpoint in PROPEL-IPF, provides an established measure of lung function in IPF patients. Qureight’s AI-powered Fibr8™ imaging biomarker complements FVC by measuring the extent of fibrosis visible on High-Resolution Computed Tomography (HRCT), providing an assessment of structural disease burden. By examining both physiological and quantitative imaging measurements, PROPEL-IPF will investigate treatment effects on both lung function and imaging-defined measures of fibrosis progression, potentially generating valuable evidence to support the development of imaging endpoints for future clinical trials.

PROPEL-IPF (NCT07284459) is a global, randomised, double-blind, placebo-controlled Phase 2 clinical trial evaluating the efficacy, safety, and tolerability of once-daily oral PIPE-791 with 26 weeks of treatment in approximately 324 people with IPF. PIPE-791 targets the lysophosphatidic acid receptor 1 (LPAR1), a clinically validated target for IPF.

Qureight recently published a Viewpoint in the European Respiratory Journal advocating for the integration of quantitative fibrosis measurements alongside established physiological endpoints in antifibrotic clinical trials1. PROPEL-IPF represents an important opportunity to try to advance this approach by potentially generating prospective evidence on the relationship between treatment-related changes in lung fibrosis and pulmonary function. This would strengthen the evidence base for quantitative CT as a sensitive measure of therapeutic response and support Qureight’s longer-term ambition to pursue formal regulatory qualification of imaging biomarkers as endpoints in antifibrotic drug development.

Simon Walsh, MD, PhD, Chief Scientific Officer, Qureight, commented: “PROPEL-IPF is a strong example of the endpoint model we believe the field needs: preserve FVC as the functional anchor, while measuring fibrosis directly on HRCT. The combination has the potential to help reveal whether a therapy is slowing the structural disease process as well as its downstream functional consequences.”

Timothy Watkins, MD, MSc, Chief Medical Officer, Contineum Therapeutics, added: “Qureight’s approach to quantitatively measure fibrosis could provide important insights in PROPEL-IPF. We are excited for our team to partner with the clinical scientists at Qureight, leveraging this imaging technology platform to enable lung-specific mechanistic insight into the effects of PIPE-791. Ultimately, this measure has the potential to serve as an additional means by which we can assess the impact of PIPE-791 treatment on underlying fibrosis pathology in IPF.”

  1. Press release (2 November 2026) Qureight publishes in the European Respiratory Journal calling for fibrosis burden to become the principal structural imaging biomarker for antifibrotic trials

Forward-Looking Statements

Certain statements contained in this press release, other than historical information, constitute forward-looking statements of Contineum Therapeutics, Inc. (“Contineum”, the “Company”, “we”, “our”, or “us”) within the meaning of the federal securities laws. Forward-looking statements include, but are not limited to, implied or express statements regarding the Company’s PROPEL-IPF clinical trial; the Company’s use of Qureight’s Fibr8 model in its PROPEL-IPF clinical trial and its ability to provide a complementary structural assessment of disease burden or to generate or provide valuable evidence or important insights; the future expectations, plans and prospects for the Company; the indications, anticipated benefits of, and market opportunities for the Company’s drug candidates; the Company’s business strategies and plans; and the quotations of the Company’s management. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company’s control and may cause its actual results, events, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties, include, but are not limited to, the following: the Company is heavily dependent on the success of PIPE-791 which is in the early stages of clinical development, and PIPE-791, and the Company’s other drug candidates, may not progress through clinical development or receive regulatory approval; the results of preclinical studies and clinical trials, including those conducted by third parties, may not be predictive of future results and unexpected adverse side effects or inadequate efficacy of the Company’s drug candidates may limit their development, regulatory approval and/or commercialization; the timing and outcome of research, development and regulatory review is uncertain; the FDA or comparable foreign regulatory authorities may disagree as to the design or implementation of our proposed clinical trials and/or require us to conduct additional studies or clinical trials or provide additional patient data, which could be costly, time-consuming and difficult to complete; clinical trials and preclinical studies may not proceed at the time or in the manner expected, or at all; the Company may use its capital resources sooner than expected and they may be insufficient to allow the Company to achieve its anticipated milestones; the potential for the Company’s programs and prospects to be negatively impacted by developments relating to the Company’s competitors, including the results of studies or regulatory determinations relating to the Company’s competitors; risks associated with reliance on third parties to successfully conduct clinical trials; the Company has incurred significant operating expenses since inception and it expects that its operating expenses will continue to significantly increase for the foreseeable future; the Company’s ability to operate in a competitive industry and compete successfully against competitors that have greater resources than the Company does; the Company may be unable to obtain, maintain and enforce intellectual property protection for its technology and drug candidates; and unstable market and economic conditions and military conflicts may adversely affect the Company’s business and financial condition and the broader economy and biotechnology industry. Additional risks and uncertainties that could affect the Company’s business, operations and results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s periodic filings and in other filings that the Company makes with the Securities and Exchange Commission (SEC) from time to time, which are available on the Company’s website at www.contineum-tx.com under the Investor section and on the SEC’s website at www.sec.gov. Accordingly, readers should not rely upon forward-looking statements as predictions of future events. Except as required by applicable law, the Company undertakes no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contacts

For further information, please contact:

Zyme Communications
Katie Odgaard

Email: katie.odgaard@zymecommunications.com
Tel: +44 (0)7787 502 947

Qureight
Rebecca Simmons, COO

Email: r.simmons@qureight.com

Contineum
Steve E. Kunszabo, Senior Director, Investor Relations & Corporate Communications

Email: skunszabo@contineum-tx.com
Tel: +1 858 649 1158

Cantourage further develops Telecan and strengthens digital access to medical care

Cantourage Group SE

/ Key word(s): Miscellaneous/Strategic Company Decision

Cantourage further develops Telecan and strengthens digital access to medical care

09.11.2026 / 09:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


  • Patient-focused development: Telecan is expanding its digital offering to provide patients seeking medical advice and treatment with an additional route to physician-led care.
  • Improved access to care: The supplementary offering is designed to address patients’ differing needs and provide greater flexibility in accessing a medical assessment.
  • Strategic development: By expanding Telecan, Cantourage is strengthening its position in digital healthcare for medical cannabis and creating long-term growth opportunities.

Cantourage Group SE (ISIN: DE000A3DSV01) is continuing the targeted development of its telemedicine platform Telecan. In addition to the existing video consultation service, the platform will offer a further digital, questionnaire-based route for physicians to review treatment requests. The aim is to provide patients with a corresponding medical need with access to physician-led care that is as straightforward and flexible as possible while maintaining medical responsibility. Through this development, Cantourage is responding to evolving requirements for digital healthcare services while further strengthening Telecan’s positioning in the German medical cannabis market.

Patient-focused development of healthcare services

Telecan has established itself as a digital point of contact for patients seeking medical advice and, where appropriate, treatment with medical cannabis. The additional digital access route is intended to offer both existing registered patients and new patients another way to have their medical treatment needs assessed by a physician. The focus is not on use of the platform itself, but on providing appropriate medical care tailored to patients’ needs. The supplementary access route is designed to accommodate differing personal and medical requirements and make the process of obtaining a medical assessment more flexible. In doing so, Telecan is systematically building on its existing healthcare offering.

Expanded digital care pathway

Under the new offering, patients can initially submit their medical information through a structured digital questionnaire. A licensed physician assesses each case individually, may ask follow-up questions or arrange an additional consultation, and independently decides whether a prescription is appropriate. The offering is structured in accordance with the applicable medical and legal requirements.
In Cantourage’s view, this additional care pathway complements Telecan’s existing services with a form of physician contact that is already established in digital healthcare.
Paul Thies, Managing Director of Apsat GmbH (Telecan), comments: “By further developing Telecan, we aim to make it easier for patients to access a qualified medical assessment. This additional digital pathway expressly does not constitute automated prescribing. Every treatment case is reviewed individually by a licensed physician, who arranges direct physician-patient contact whenever medically or legally necessary. We consistently adhere to the applicable medical and regulatory requirements and have developed the platform further so that we can also respond flexibly to future legislative changes. Our aim is to make meaningful use of digital opportunities while ensuring high standards of medical quality and regulatory compliance.”

Strategic significance for Cantourage

Telecan is an important element of Cantourage’s strategic positioning in the German medical cannabis market. The platform supports access to care provided under physicians’ responsibility and contributes to the ongoing development of digital healthcare structures in this field.
For Cantourage, this may indirectly create additional commercial opportunities in its pharmacy business. The company generates its product revenue from the distribution of medical cannabis products to pharmacies, rather than from the telemedicine platform itself.
Philip Schetter, CEO of Cantourage Group SE, comments: “By further developing Telecan, we are putting patients’ needs at the centre of our efforts. Our goal is to provide people with a corresponding medical need with modern, responsible access to physician-led care. At the same time, we are strengthening Cantourage’s strategic position in the medical cannabis market. We believe that the patient-focused development of digital healthcare services can also provide positive momentum for our business over the long term.”

About Cantourage
Cantourage is a leading European company engaged in the production and distribution of medical cannabis preparations and pharmaceutical products. With its experienced management team and “Fast Track Access” platform, Cantourage enables producers from around the world to gain faster, easier and more cost-effective access to the growing European medical cannabis market. To this end, the company processes and distributes cannabis raw materials and extracts, consistently ensuring compliance with the highest European pharmaceutical quality standards. Cantourage offers pharmaceutical-grade products across all relevant market segments: dried cannabis flowers, extracts, dronabinol and cannabidiol. Cantourage has been listed on the Frankfurt Stock Exchange since 11 November 2022 (ISIN: DE000A3DSV01).

 


09.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Cantourage Group SE
Feurigstraße 54
10827 Berlin
Germany
E-mail: info@cantourage.com
Internet: https://www.cantourage.com/
ISIN: DE000A3DSV01
WKN: A3DSV0
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate BSX
LEI Code: 3912003NCTLO6YHA9V48
EQS News ID: 2430492

 
End of News EQS News Service

2430492  09.11.2026 CET/CEST

Sandoz launches new semaglutide treatment option in Brazil, expanding patient access to GLP-1 medicine in key global market

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

MEDIA RELEASE
 

  • First Sandoz semaglutide launch comes in one of world’s largest and fastest-growing GLP-1 markets
  • More than 16.5 million Brazilians live with diabetes; disease remains key public health challenge in Brazil
  • Builds on recent milestones including semaglutide regulatory approval in Canada and tirzepatide FDA file acceptance in US

 

Basel, 9 November 2026 – Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, today announces the launch of Owozy™ (semaglutide solution for injection) in Brazil, expanding patient access to a new high-quality semaglutide treatment option in one of the world’s largest and fastest-growing GLP-1 markets1.

Owozy was developed by Adalvo and was approved by the Agência Nacional de Vigilância Sanitária (ANVISA) on 29 July 2026 for the treatment of type-2 diabetes. It will be commercialised in Brazil by local partner Biolab & Co under a distribution and promotion agreement signed earlier this year. Owozy is available in a pre-filled delivery system (multi-dose disposable pen) designed to facilitate use by both patients and healthcare professionals. It is among the earliest new semaglutide treatment options available in Brazil, where the GLP-1 market is valued at an estimated USD 2.7 billion2.

Richard Saynor, Sandoz Chief Executive Officer, says: “Our first semaglutide launch marks a historic moment both for Sandoz and for patients in Brazil. Owozy will bring a high-quality treatment option to patients with type-2 diabetes in this major global market, where the disease represents a key public health challenge, while supporting the sustainability of the local healthcare system. It also builds momentum behind our overall GLP-1 strategy and our ambition to be a leading player in the generic GLP-1 market.”

It is estimated that more than 16.5 million adults in Brazil live with diabetes, including type-2 diabetes, placing the country among those with the highest prevalence worldwide3. In addition, around one in three people with diabetes are still undiagnosed, representing more than five million individuals in Brazil4. Even diagnosed patients face barriers to adequate treatment, reinforcing the need to expand the availability of effective and accessible therapies across the country5.

The launch advances the GLP-1 strategy presented at the September 2026 Sandoz Capital Markets Day, including early semaglutide market launches in Brazil and Canada. It also builds on other recent GLP-1 milestones, including regulatory approval for Sandoz® Semaglutide (semaglutide) in Canada and US regulatory submission acceptance for in-house development of generic tirzepatide. Overall, it underlines the Sandoz commitment to help millions of patients access generic and biosimilar medicines sustainably and affordably through a global portfolio of more than 1,300 medicines, supported by an industry-leading pipeline of over 300 additional generic programmes.

No material financial contribution from the Sandoz launch of semaglutide is expected this year.
 

About Owozy (semaglutide)
Owozy is a semaglutide 1.34 mg/mL solution for injection for adults with insufficiently controlled type-2 diabetes mellitus. It is used alongside diet and exercise, either as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in combination with other medicines for the treatment of diabetes.

Approved presentations include semaglutide 1.34 mg/mL solution for injection in a 1.5 mL pre-filled pen and semaglutide 1.34 mg/mL solution for injection in a 3.0 mL pre-filled pen.

Owozy is administered once weekly, in accordance with the approved product information and medical advice. The available presentations have been developed in accordance with applicable technical requirements and international standards, with consideration for consistent treatment administration, appropriate use, and the needs of adults with type-2 diabetes.
 

DISCLAIMER
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law.

REFERENCES
1 Data on file. Based on IQVIA forecast link data, MAT06 2026
2 Data on file. Based on IQVIA analytics link data, MAT09 2026
3 International Diabetes Federation. Brazil: Diabetes country report 2000 – 2050. Available at: Diabetes Data in Brazil | IDF Diabetes Atlas [Last accessed: November 2026]
4 International Diabetes Federation. Brazil: Diabetes country report 2000 – 2050. Available at: Diabetes Data in Brazil | IDF Diabetes Atlas [Last accessed: November 2026]
5 International Diabetes Federation. Brazil: Diabetes country report 2000 – 2050. Available at: Diabetes Data in Brazil | IDF Diabetes Atlas [Last accessed: November 2026]

ABOUT SANDOZ
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in affordable medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 colleagues of 100 nationalities work together to ensure over one billion patients are reached by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 medicines addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. In 2026, Sandoz celebrates 20 years of pioneering biosimilars, 80 years of antibiotics manufacturing and 140 years of heritage. In 2025, Sandoz recorded net sales of USD 11.1 billion.  

 

CONTACTS

Global Media Relations contacts

Investor Relations contacts

Global.MediaRelations@sandoz.com

Investor.Relations@sandoz.com

Alexis Kalomparis

+41 792 790285

Craig Marks

+44 7818 942 383

Marina Konrad-Maerk

+41 79 487 79 89 

Tamara Hackl

+41 79 790 5217

Gregor Rodehueser

+49 170 574 3200

Silvia Siegfried

+41 79 795 9061